Published in PLoS One on June 21, 2010
Recent Development in Carbohydrate Based Anti-cancer Vaccines. J Carbohydr Chem (2012) 0.98
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin Dev Immunol (2012) 0.96
Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One (2012) 0.92
Clustered carbohydrates in synthetic vaccines. Chem Soc Rev (2012) 0.91
A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity. Angew Chem Int Ed Engl (2014) 0.85
Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. Chembiochem (2014) 0.84
Synthesis of heteroglycoclusters by using orthogonal chemoselective ligations. Beilstein J Org Chem (2012) 0.83
Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells. J Immunol (2014) 0.80
Recent progress in antitumoral synthetic vaccines. ACS Med Chem Lett (2014) 0.76
Synthetic self-adjuvanting glycopeptide cancer vaccines. Front Chem (2015) 0.76
Role of a Preorganized Scaffold Presenting Four Residues of a GM-3 Lactone Mimetic on Melanoma Progression. ACS Med Chem Lett (2015) 0.75
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev (2004) 3.98
Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity (2009) 3.91
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A (2006) 3.19
Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev (2005) 2.98
Vaccine adjuvants: current state and future trends. Immunol Cell Biol (2004) 2.74
Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol (2001) 2.42
Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity (2007) 2.42
Robust immune responses elicited by a fully synthetic three-component vaccine. Nat Chem Biol (2007) 2.24
Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Berl) (1997) 2.21
Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol (2004) 1.97
Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest (2000) 1.88
Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta (2007) 1.70
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 1.60
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest (2010) 1.58
Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood (2004) 1.56
Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology (2005) 1.50
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen. Angew Chem Int Ed Engl (2005) 1.49
Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol (2005) 1.45
Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun (1991) 1.42
Lipopeptide vaccines--yesterday, today, and tomorrow. Lancet Infect Dis (2002) 1.41
Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol (1997) 1.39
Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjug Chem (2005) 1.36
Dendritic cells resurrect antigens from dead cells. Trends Immunol (2001) 1.35
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res (2003) 1.32
Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent. J Biol Chem (2004) 1.31
Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci U S A (2009) 1.29
Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Proc Natl Acad Sci U S A (2004) 1.27
Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res (2009) 1.26
A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res (2004) 1.26
IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol (2006) 1.26
Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: implications for diagnostic and vaccine development. Chembiochem (2005) 1.24
Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J Immunol (2008) 1.24
In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol (2003) 1.16
A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol (2008) 1.16
Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med (2006) 1.15
Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol (2004) 1.14
Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol (2002) 1.12
Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc Natl Acad Sci U S A (2001) 1.12
Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol (2002) 1.10
Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol (2005) 1.10
Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem (2009) 1.09
The many roads to cross-presentation. J Exp Med (2005) 1.08
Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol (2006) 1.06
A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol (2010) 1.06
Mini-review CD4 T cells are required for CD8 T cell memory generation. Eur J Immunol (2003) 1.05
High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine (2000) 1.05
Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol (2009) 1.05
Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology (2002) 1.04
Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem (2008) 1.03
The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol (2005) 1.03
Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol (2000) 1.02
Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II. J Immunol (2008) 1.01
Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett (2007) 1.01
Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships. Vaccine (2004) 1.01
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res (2004) 1.00
Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentation by MHC class I molecules. Curr Opin Immunol (2006) 1.00
Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol Immunother (2008) 1.00
Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest Ophthalmol Vis Sci (2007) 0.99
B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep (2010) 0.97
The delivery of an antigen from the endocytic compartment into the cytosol for cross-presentation is restricted to early immature dendritic cells. Immunology (2006) 0.96
New tools for antigen delivery to the MHC class I pathway. Trends Immunol (2004) 0.96
Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol (2005) 0.96
Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul Surf (2006) 0.95
New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses (2006) 0.94
Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clin Vaccine Immunol (2010) 0.94
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS (2006) 0.94
Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol (2004) 0.94
Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol (2010) 0.92
Classical MHC class I peptide presentation of a bacterial fusion protein by bone marrow-derived dendritic cells. Eur J Immunol (1999) 0.91
Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. J Pept Res (2003) 0.91
Dendritic cells use endocytic pathway for cross-priming class Ib MHC-restricted CD8alphaalpha+TCRalphabeta+ T cells with regulatory properties. J Immunol (2009) 0.90
CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother (2010) 0.90
Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin. J Immunol (2006) 0.90
Cross-presentation of antigens by dendritic cells. Crit Rev Immunol (2002) 0.89
TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett (2009) 0.89
Toll-like receptors in innate immunity: role of bacterial endotoxin and toll-like receptor 4 in endometrium and endometriosis. Gynecol Obstet Invest (2009) 0.88
Rational Peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem (2005) 0.87
Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect Immun (2004) 0.87
Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines (2008) 0.85
Lipopeptide presentation pathway in dendritic cells. Immunol Lett (2001) 0.84
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol Immunol (2008) 0.83
Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy. J Immunol (2004) 0.83
Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol (2003) 0.83
The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother (2009) 0.82
Adjuvant therapy for colorectal cancer: present and future perspectives. Dis Colon Rectum (1997) 0.82
CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev (2009) 0.82
Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. Arch Immunol Ther Exp (Warsz) (2009) 0.82
The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth. Biomaterials (2009) 0.82
Correlation analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma. Oncology (2004) 0.82
Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses. Int Immunol (2001) 0.81
Alternative processing for MHC class I presentation by immature and CpG-activated dendritic cells. Eur J Immunol (2004) 0.80
Trafficking of exogenous peptides into proteasome-dependent major histocompatibility complex class I pathway following enterotoxin B subunit-mediated delivery. J Biol Chem (2004) 0.80
Preparation of a multiple antigen glycopeptide (MAG) carrying the Tn antigen. A possible approach to a synthetic carbohydrate vaccine. J Pept Res (1997) 0.80
Mucins as immunogenic targets in cancer. Anticancer Res (2000) 0.79
Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br J Cancer (2005) 0.79
Lipopeptide vaccines--yesterday, today, and tomorrow. Lancet Infect Dis (2002) 1.41
Controlled density patterning of tolylterpyridine-tagged oligonucleotides. Langmuir (2011) 1.38
A gene capable of blocking apoptosis can substitute for the herpes simplex virus type 1 latency-associated transcript gene and restore wild-type reactivation levels. J Virol (2002) 1.37
Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjug Chem (2005) 1.36
Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem (2007) 1.34
Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc (2004) 1.32
A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5' end of the latency-associated transcript produces a protein in infected rabbits. J Virol (2002) 1.30
SOD1: a candidate gene for keratoconus. Invest Ophthalmol Vis Sci (2006) 1.26
A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res (2004) 1.26
Mitochondrial DNA haplogroups associated with age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.26
HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol (2008) 1.24
Regulation of caspase 8- and caspase 9-induced apoptosis by the herpes simplex virus type 1 latency-associated transcript. J Neurovirol (2002) 1.20
Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J Virol (2003) 1.19
The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol (2011) 1.18
In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors. Mol Cancer (2007) 1.17
Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol (2004) 1.14
The herpes simplex virus type 1 latency-associated transcript can protect neuron-derived C1300 and Neuro2A cells from granzyme B-induced apoptosis and CD8 T-cell killing. J Virol (2010) 1.12
Identification of herpes simplex virus type 1 latency-associated transcript sequences that both inhibit apoptosis and enhance the spontaneous reactivation phenotype. J Virol (2003) 1.12
Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4. Mol Imaging (2006) 1.12
Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther (2009) 1.09
Herpes simplex virus type 1 mutants containing the KOS strain ICP34.5 gene in place of the McKrae ICP34.5 gene have McKrae-like spontaneous reactivation but non-McKrae-like virulence. J Gen Virol (2002) 1.09
Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine (2011) 1.07
New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines (2009) 1.07
Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol (2006) 1.06
Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice. J Virol (2008) 1.06
A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol (2010) 1.06
Stable cell lines expressing high levels of the herpes simplex virus type 1 LAT are refractory to caspase 3 activation and DNA laddering following cold shock induced apoptosis. Virology (2007) 1.04
Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J Virol (2008) 1.04
Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem (2008) 1.03
Multivalent glyco(cyclo)peptides. Chem Soc Rev (2012) 1.02
Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol Immunother (2008) 1.00
Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest Ophthalmol Vis Sci (2007) 0.99
The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity. Invest Ophthalmol Vis Sci (2009) 0.99
Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands. Org Biomol Chem (2006) 0.99
Properties of some variants of human beta2-microglobulin and amyloidogenesis. J Biol Chem (2003) 0.98
1-Ethoxyethylidene, a new group for the stepwise SPPS of aminooxyacetic acid containing peptides. J Org Chem (2008) 0.98
The latency-related gene encoded by bovine herpesvirus 1 can suppress caspase 3 and caspase 9 cleavage during productive infection. J Neurovirol (2004) 0.97
Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses. Invest Ophthalmol Vis Sci (2011) 0.96
Mitochondrial DNA variants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration. PLoS One (2013) 0.96
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin Dev Immunol (2012) 0.96
New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors. Mol Ther (2005) 0.96
In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging (2007) 0.96
Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul Surf (2006) 0.95
Hepatocyte targeting and intracellular copper chelation by a thiol-containing glycocyclopeptide. J Am Chem Soc (2010) 0.95
Alu DNA polymorphism in ACE gene is protective for age-related macular degeneration. Biochem Biophys Res Commun (2002) 0.94
Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clin Vaccine Immunol (2010) 0.94
Oxime bond formation for the covalent attachment of oligonucleotides on glass support. Bioorg Med Chem Lett (2003) 0.94
In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4). Mol Imaging (2007) 0.93
Oxysterol-induced toxicity in R28 and ARPE-19 cells. Neurochem Res (2003) 0.93
Methods for detecting the HSV-1 LAT anti-apoptosis activity in virus infected tissue culture cells. J Virol Methods (2004) 0.93
Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol (2010) 0.92
A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine (2011) 0.92
Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling. J Virol (2012) 0.92
In vivo molecular imaging of atherosclerotic lesions in ApoE-/- mice using VCAM-1-specific, 99mTc-labeled peptidic sequences. J Nucl Med (2013) 0.92
Oxime ligation: a chemoselective click-type reaction for accessing multifunctional biomolecular constructs. Chemistry (2013) 0.92
Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin Vaccine Immunol (2008) 0.92
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. Future Virol (2012) 0.92
Mitochondrial DNA haplogroups confer differences in risk for age-related macular degeneration: a case control study. BMC Med Genet (2013) 0.91
A herpes simplex virus type 1 mutant with gamma 34.5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice. Neurosurgery (2002) 0.90
The herpes simplex virus type 1 latency-associated transcript inhibits phenotypic and functional maturation of dendritic cells. Viral Immunol (2012) 0.90
In vivo molecular imaging of myocardial angiogenesis using the alpha(v)beta3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol (2010) 0.90
Introducing point mutations into the ATGs of the putative open reading frames of the HSV-1 gene encoding the latency associated transcript (LAT) reduces its anti-apoptosis activity. Microb Pathog (2007) 0.89
3-nitro-3-deaza-2'-deoxyadenosine as a versatile photocleavable 2'-deoxyadenosine mimic. J Am Chem Soc (2004) 0.88
Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model. Cancer Biother Radiopharm (2008) 0.88